George Cipolletti, president and CEO of OMNI, said: “Gaining the distribution rights to SERF’s NOVAE line of Dual Mobility Acetabular Cups will allow OMNI to provide its customers with access to large head hip articulation technology that is free from the risk of metal ION release. The SERF Dual Mobility Cup System has a successful clinical history of over 30 years with outstanding implant longevity and extremely low complication rates.

“Combining this Ion Free, Large Head Dual Mobility Acetabular Cup technology with OMNI’s advanced Apex Modular and K2 Modular hip stems as well as the new Apex ARC™ Tissue Sparing Hip Stem systems will, upon FDA approval, provide OMNI with the ability to compete against the Metal on Metal large head acetabular cup technology of our competitors without the risks that have recently been associated with Metal on Metal bearing surfaces.”

Nik Nikolaev, chairman of Orthopaedic Synergy, the holding company that owns OMNIlife science, and Enztec, said: “Our distribution arrangement with SERF is in keeping with our philosophy of providing the best technology to our customers whether developed in house by our own family of companies or by partnering with very high quality manufacturers such as SERF-Dedienne Sante.”

OMNIlife science designs, manufactures and distributes orthopaedic devices for total joint replacement patients.

SERF-Dedienne Sante is a French medical implant company and is a manufacturer and distributor of orthopedic and dental implants. Dual Mobility Acetabular Cup Concept has been invented by Dr Gilles Bousquet in the mid 1970’s and is currently generating an interest from the orthopedic community based upon widely published long term clinical results.